HC Wainwright & Co. Maintains Buy on WAVE Life Sciences, Lowers Price Target to $13
Benzinga Newsdesk 5 months ago
NewsPrice TargetAnalyst Ratings
HC Wainwright & Co. analyst Andrew S. Fein maintains WAVE Life Sciences (NASDAQ:WVE) with a Buy and lowers the price target from $18 to $13.
HC Wainwright & Co. analyst Andrew S. Fein maintains WAVE Life Sciences (NASDAQ:WVE) with a Buy and lowers the price target from $18 to $13.